# EXTRA-PC (NCT06312670)

> Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: masofaniten (EPI-7386) plus enzalutamide plus androgen deprivation therapy
- Indication: treatment-naïve metastatic hormone-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06312670
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Pedro Barata, MD, MSc
- Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Prostate Adenocarcinoma
- Interventions: EPI-7386; Enzalutamide; Androgen Deprivation Therapy (ADT)
- Enrollment: 13
- Primary outcome: Biochemical response rate
- Primary outcome: PSA progesterone-free survival (PFS)
- Primary outcome: Radiographic PFS (rPFS)
- Primary outcome: ORR (confirmed)

## Indexed commentary on EXTRA-PC so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=extra-pc-nct06312670
